CureVac (NASDAQ:CVAC - Free Report) - Stock analysts at Leerink Partnrs boosted their FY2025 earnings estimates for shares of CureVac in a report released on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($0.54) per share for the year, up from their previous forecast of ($0.60). The consensus estimate for CureVac's current full-year earnings is $0.72 per share.
CureVac Stock Performance
Shares of CureVac stock traded down $0.10 on Friday, hitting $3.87. The stock had a trading volume of 472,755 shares, compared to its average volume of 1,397,851. The business's 50 day moving average is $3.31 and its two-hundred day moving average is $3.19. The stock has a market cap of $865.30 million, a price-to-earnings ratio of 7.03 and a beta of 2.50. CureVac has a twelve month low of $2.21 and a twelve month high of $5.28. The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05.
Hedge Funds Weigh In On CureVac
Several institutional investors and hedge funds have recently modified their holdings of CVAC. Point72 Asset Management L.P. bought a new stake in shares of CureVac in the second quarter valued at approximately $8,237,000. Barclays PLC bought a new stake in CureVac during the third quarter worth about $67,000. Public Employees Retirement System of Ohio bought a new stake in shares of CureVac during the 3rd quarter worth approximately $91,000. Jane Street Group LLC boosted its position in shares of CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company's stock worth $235,000 after acquiring an additional 55,867 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in CureVac by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company's stock valued at $127,000 after purchasing an additional 16,792 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.
About CureVac
(
Get Free Report)
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.
Featured Articles
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
